Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Hayes

Physician Assistant, Medical Charleston, SC Physician Assistant

NPI 1396202180 CMS profile 11206986

1616 Ashley River Rd, Charleston, SC 29407

Open in the dashboard

General payments

$12,349

673 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Hayes of Charleston, SC is reported in the CMS Open Payments database as having received $12,349 across 673 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,131 106
2024 General $2,053 112
2023 General $2,302 129
2022 General $2,415 134
2021 General $3,447 192

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Hayes
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jennifer Hayes were reported at $2,131. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jennifer Hayes Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,447 $156 $41–$563 $132
2022 $2,415 $185 $55–$649 $149
2023 $2,302 $199 $58–$717 $160
2024 $2,053 $206 $62–$740 $164
2025 $2,131 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,374 182 payments
  2. ITI, Inc. $1,396 59 payments
  3. Otsuka America Pharmaceutical, Inc. $1,037 52 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $998 52 payments
  5. Alkermes, Inc. $947 47 payments
  6. Janssen Pharmaceuticals, Inc $810 37 payments
  7. Lundbeck LLC $809 39 payments
  8. Sunovion Pharmaceuticals Inc. $770 36 payments
  9. Axsome Therapeutics, Inc. $652 29 payments
  10. Vanda Pharmaceuticals Inc. $374 18 payments
  11. Other $2,183 122 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,334 672 payments
  2. Education $15 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,676 137 payments
  2. CAPLYTA $1,024 44 payments
  3. TRINTELLIX $998 52 payments
  4. REXULTI Psychiatry $794 42 payments
  5. LATUDA $784 37 payments
  6. SPRAVATO $701 31 payments
  7. REXULTI Psychiatry $681 34 payments
  8. VIVITROL $597 27 payments
  9. Auvelity $531 24 payments
  10. FANAPT $374 18 payments
  11. Other $6,627 366 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

922

Median for Addiction Medicine: 227

Drug cost

$61,725

Median for Addiction Medicine: $23,125

Branded share of claims

20.6%

Median for Addiction Medicine: 56%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 14 $23,240
Invega Sustenna Paliperidone Palmitate Brand 11 $19,705
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 24 $3,848
Pregabalin Generic 12 $1,944
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 16 $1,507
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 34 $1,162
Bupropion Xl Bupropion Hcl Brand 43 $978
Sertraline Hcl Generic 76 $884
Naltrexone Hcl Generic 21 $882
Lamotrigine Generic 63 $728

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 382 Part D prescribers listed as Addiction Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$23,773

Medicare's payments for the services billed

Medicare patients

18

Average age 61

Services billed

410

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
Ischemic heart disease 0%
Atrial fibrillation 0%
Chronic kidney disease 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $237
  • Otsuka America Pharmaceutical, Inc. $120
$357 14 —
VRAYLAR
  • AbbVie, Inc. $333
$333 — —
CAPLYTA
  • ITI, Inc. $166
$166 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $149
$149 — —
Azstarys
  • Corium, Inc. $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

673 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record